Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
CHL is strengthening its play in the fast-growing beauty and personal care sector
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Global Phase-3 study initiation expected in the second half of 2024
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
A significant proportion of healthcare professionals still tend to favor branded drugs
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Subscribe To Our Newsletter & Stay Updated
